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Purpose: To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330), trials of rani-
bizumab in diabetic macular edema (DME).
Design: Phase III, randomized, multicenter, double-masked, 3-year trials, sham injectionecontrolled for
2 years.
Participants: Adults with DME (n¼759), baseline best-corrected visual acuity (BCVA) 20/40 to 20/320
Snellen equivalent, and central foveal thickness (CFT) 275 mm on optical coherence tomography.
Methods: Patients were randomized equally (1 eye per patient) to monthly 0.5 mg or 0.3 mg ranibizumab or
sham injection. In the third year, sham patients, while still masked, were eligible to cross over to monthly 0.5 mg
ranibizumab. Macular laser was available to all patients starting at month 3; panretinal laser was available as
necessary.
Main Outcome Measures: The proportion of patients gaining 15 Early Treatment Diabetic Retinopathy
Study letters in BCVA from baseline at month 24.
Results: Visual acuity (VA) outcomes seen at month 24 in ranibizumab groups were consistent through month
36; the proportions of patients who gained 15 letters from baseline at month 36 in the sham/0.5 mg, 0.3 mg, and
0.5 mg ranibizumab groups were 19.2%, 36.8%, and 40.2%, respectively, in RIDE and 22.0%, 51.2%, and 41.6%,
respectively, in RISE. In the ranibizumab arms, reductions in CFT seen at 24 months were, on average, sustained
through month 36. After crossover to 1 year of treatment with ranibizumab, average VA gains in the sham/0.5 mg
group were lower compared with gains seen in the ranibizumab patients after 1 year of treatment (2.8 vs. 10.6 and
11.1 letters). Per-injection rates of endophthalmitis remained low over time (w0.06% per injection). The incidence
of serious adverse events potentially related to systemic vascular endothelial growth factor inhibition was 19.7% in
patients who received 0.5 mg ranibizumab compared with 16.8% in the 0.3 mg group.
Conclusions: The strong VA gains and improvement in retinal anatomy achieved with ranibizumab at month
24 were sustained through month 36. Delayed treatment in patients receiving sham treatment did not seem to
result in the same extent of VA improvement observed in patients originally randomized to ranibizumab. Ocular
and systemic safety was generally consistent with the results seen at month 24.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
Ophthalmology 2013;120:2013-2022
ª 2013 by the American Academy of Ophthalmology.
*Group members listed online (available at http://aaojournal.org).
Open access under CC BY-NC-ND license.In 1985, the Early Treatment Diabetic Retinopathy Study
(ETDRS) established macular laser photocoagulation as the
standard of care for diabetic macular edema (DME).1
Despite widespread use of macular laser for the past
quarter-century, its mechanism of action still remains
largely unknown. In contrast, Folkman’s pioneering work in
angiogenesis led to the discovery of precise molecular
mechanisms that could be speciﬁcally targeted in cancer,
macular degeneration, and diabetic retinopathy (DR).2 The
subsequent cloning of vascular endothelial growth factor
 2013 by the American Academy of Ophthalmology
Published by Elsevier Inc. Open access under CC BY-NC-ND license.(VEGF) A by Ferrara and Henzel3 and the creation of
highly speciﬁc VEGF antagonists led to targeted therapy
for DME with ranibizumab, a monoclonal antibody
fragment (Fab, or antigen-binding fragment) that potently
inhibits VEGF.4 Randomized prospective clinical trials have
demonstrated that intravitreal inhibition of VEGF with
ranibizumab, given monthly for up to 24 months or less
frequently using a variety of as-needed regimens, results
in rapid and sustained improvements in vision and retinal
anatomy in patients with DME.5e9
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clinical trials that enrolled a total of 759 patients with vision
loss from DME (best-corrected visual acuity [BCVA], 20/
40e20/320 Snellen equivalent, and documented macular
edema with central subﬁeld thickness 275 mm on time-
domain optical coherence tomography [OCT]), with the
objective of evaluating the efﬁcacy and safety of intravitreal
ranibizumab for DME. The 24-month sham-controlled
outcomes, previously published in Ophthalmology,
demonstrated that the response to intravitreal inhibition of
VEGF was rapid and substantial.7 Compared with the
control treatment of sham injections plus macular laser per
protocol-speciﬁed criteria, statistically signiﬁcant improve-
ments in BCVA and reductions in retinal thickness were
observed on average as early as 7 days after the ﬁrst rani-
bizumab injection; these improvements were maintained to
24 months. Furthermore, in the ﬁrst 2 years of RIDE and
RISE, fewer patients treated with ranibizumab experienced
signiﬁcant vision loss (15 ETDRS letters), and fewer
patients treated with ranibizumab developed proliferative
DR.10 The ocular safety of ranibizumab in patients with
DME was consistent with previous phase III studies of
ranibizumab in DME, age-related macular degeneration,
and retinal vein occlusion.5,10e14
Although sham-controlled for only the ﬁrst 24 months,
the RIDE and RISE studies continued after the primary
analysis so that additional questions could be addressed.
The study design allowed for patients in the sham control
group to cross over and receive monthly 0.5 mg ranibizu-
mab injections in the third year. Patients originally
randomized to ranibizumab were maintained in a masked
fashion on their originally assigned regimens of monthly
0.3 or 0.5 mg. The additional data provide for evaluation of
3 important clinical questions: (1) Are the results seen after
24 months of ranibizumab treatment maintained over
a third year of monthly therapy? (2) What is the effect, if
any, of delayed initiation of treatment with ranibizumab in
the sham crossover group? (3) Which tested dose of rani-
bizumab should be recommended over the long term for
patients with DME, a population that differs from other
populations with retinal disease treated with anti-VEGF
therapy in having a higher likelihood of bilateral disease5
and an elevated risk of cardiovascular events and
mortality?15,16 In this report, the ongoing efﬁcacy and
safety of monthly injections of 0.3 mg and 0.5 mg ranibi-
zumab for DME through 36 months are presented, and the
questions are addressed.
Methods
RIDE (registered on ClinicalTrials.gov as NCT00473382; accessed
September 15, 2012) and RISE (registered on ClinicalTrials.gov as
NCT00473330; accessed September 15, 2012) are methodologically
identical, phase III, randomized, multicenter, double-masked, 3-year
trials that were sham injectionecontrolled for the ﬁrst 2 years.
Adults with decreased vision due to center-involved DME and the
presence of macular edema documented on OCT were eligible to
enroll. Both trials were designed and conducted in accordance with
the principles of the Declaration of Helsinki and in compliance with
the Health Insurance Portability and Accountability Act. The study2014protocols were approved by institutional review boards, ethics
committees, or as applicable. All patients provided written informed
consent before enrolling as study participants.
The study methods have been reported in detail elsewhere.7
Upon completion of the 24-month sham-controlled treatment
period (time point for the primary efﬁcacy outcome), sham patients
were eligible to cross over to receive treatment with monthly 0.5
mg ranibizumab. Of note, to preserve study masking, all patients
were asked if they wanted to cross over, but only patients
randomized to sham injection were actually crossed over by the
study management computer system. After a protocol amendment
in 2010, sham patients who met predeﬁned vision loss and OCT
criteria became eligible for early (before month 25) crossover to
active treatment with monthly 0.5 mg ranibizumab starting in mid-
2010. Patients with study eyes originally randomized to 0.3 or 0.5
mg ranibizumab continued on the monthly schedule to which they
originally had been assigned. All patients remained eligible for per-
protocol macular laser beginning at month 3 and throughout the
duration of the 36-month treatment period on the basis of pre-
speciﬁed subjective and objective criteria.
Outcomes
The primary efﬁcacy outcome measure was the proportion of
patients who gained 15 ETDRS letters in BCVA score at month
24 compared with baseline. Secondary outcome measures at month
36 were analogous to the 24-month outcomes and included the
proportion of patients who had gained 15 letters from baseline at
month 36, mean change from baseline in BCVA score over time,
proportion of patients who lost <15 letters in BCVA score
compared with baseline, proportion of patients with BCVA Snellen
equivalent of 20/40 or better, and mean change from baseline in
central foveal thickness (CFT) over time, as assessed on OCT by
the central reading center. Exploratory outcomes included the
proportion of patients with OCT CFT 250 mm and the proportion
of patients progressing to proliferative DR.
Analysis
The statistical methods used to analyze the data have been
described in detail elsewhere.7 Analyses for efﬁcacy end points
were based on the intent-to-treat (ITT) population, with patients
grouped according to their assigned treatment. The methods used
to analyze the 36-month efﬁcacy were the same as those described
for the analysis of the 24-month end points; however, because most
patients in the sham group crossed over to receive 0.5 mg ranibi-
zumab monthly in the third year of treatment, analyses of 36-month
efﬁcacy data consisted of descriptive statistics by treatment group
with limited formal comparisons made post hoc. Comparisons of
efﬁcacy at month 36 were between patients actively treated for 3
years (with monthly 0.3 or 0.5 mg ranibizumab) versus patients
treated with sham for 2 years followed by treatment for up to 1 year
with monthly 0.5 mg ranibizumab. Missing data were imputed by
last observation carried forward.
Safety analyses were based on the safety-evaluable population,
deﬁned as patients who received at least 1 dose of study drug.
Patients were grouped according to the treatment received. Patients
randomized to sham who inadvertently received treatment with the
active study drug were classiﬁed in the active drug treatment
group. For the sham group, safety outcomes were summarized
during the 24-month sham-controlled period and separately for the
sham/0.5 mg group during the 36-month study. The sham/0.5 mg
group consists of patients who received sham only and patients
who crossed over to receive treatment with monthly 0.5 mg rani-
bizumab in the third year of treatment.
Table 1. Patient Retention and Drug Exposure through Month 36
Category
RIDE RISE
Sham/0.5 mg
(N¼130)
Ranibizumab Sham/0.5 mg
(N¼127)
Ranibizumab
0.3 mg (N¼125) 0.5 mg (N¼127) 0.3 mg (N¼125) 0.5 mg (N¼125)
On study at month 24, n (%) 108 (83.1) 105 (84.0) 110 (86.6) 102 (80.3) 105 (84.0) 106 (84.8)
On study at month 36, n (%) 102 (78.5) 98 (78.4) 98 (77.2) 86 (67.7) 98 (78.4) 100 (80.0)
Drug exposure (ranibizumab or
sham injections)
Months 25e36* 1e36 1e36 25e36* 1e36 1e36
No. of patients 101y 125 124 89y 125 125
Total No. of injections 1015 3499 3765 881 3724 3562
Per patient
Mean (SD) 10.0 (1.8) 28.0 (11.2) 30.4 (9.2) 9.9 (2.3) 29.8 (10.2) 28.5 (10.4)
Median 11 34 34 11 35 34
SD ¼ standard deviation.
*Reﬂects 1 year of ranibizumab 0.5 mg exposure after crossover.
yNumber of patients originally randomized to sham who crossed over to ranibizumab 0.5 mg.
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Patient Disposition
A total of 594 patients (78.3%) received ranibizumab treatment
after month 24. At month 36, the proportion of patients remaining
in the study varied from 67.7% to 80.0% across the treatment
groups (Table 1). Among the 210 sham patients from both studies
remaining in the study at month 24 (of 257 originally randomized
to sham), a total of 190 (91%) crossed over to active treatment with
monthly 0.5 mg ranibizumab. In the 2 studies, 5 sham patients
(2.6%) crossed over early, at month 23. The median number of
ranibizumab injections received by the patients in the sham and
crossover to 0.5 mg group after crossover (between months 25
and 36) was 11, whereas patients originally randomized to
ranibizumab received a median of 34 to 35 injections over their
3-year treatment period (Table 1).
Visual Acuity Outcomes
Continued treatment with ranibizumab through month 36 resulted
in maintenance of the efﬁcacy outcomes seen at earlier time points.
At the 3-year time point, in RIDE, 36.8% of patients receiving 0.3
mg ranibizumab and 40.2% of patients receiving 0.5 mg ranibi-
zumab had gained 15 ETDRS letters in BCVA from baseline,
compared with 19.2% of patients treated with sham/0.5 mg
(P¼0.0026 for comparison of 0.3 mg with sham/0.5 mg, P¼0.0001
for comparison of 0.5 mg with sham/0.5 mg in post hoc stratiﬁed
calculations; Fig 1 and Table 2). In RISE, corresponding
proportions were 51.2%, 41.6%, and 22.0%, respectively
(P< 0.0001 for comparison of 0.3 mg with sham/0.5 mg,
P¼0.0005 for comparison of 0.5 mg with sham/0.5 mg in post
hoc stratiﬁed calculations; Fig 1 and Table 2).
Consistent with the maintenance of efﬁcacy measured in terms
of 15-letter improvement, the average change in BCVA from
baseline achieved at month 24 was sustained through month 36 in
patients originally randomized to ranibizumab (Fig 2). In RIDE, the
mean number of ETDRS letters change from baseline at month 24
versus change from baseline at month 36 in patients randomized to
sham, 0.3 mg, and 0.5 mg ranibizumab was 2.3 versus 4.7, 10.9
versus 10.6, and 12.0 versus 11.4, respectively. In RISE, the
corresponding numbers were 2.6 versus 4.3, 12.5 versus 14.2,
and 11.9 versus 11.0 (Fig 2). The efﬁcacy of the 0.3-mg and0.5-mg doses of ranibizumab was similar over 36 months, as
demonstrated in efﬁcacy data pooled from RIDE and RISE (Fig 3).
Other measures of BCVA outcome also were consistent with
the results previously observed at month 24. At month 36, fewer
patients originally randomized to ranibizumab had lost 15 letters
from baseline (0.8%e3.9%), compared with patients originally
randomized to sham (7.7, 8.7%; Fig 1). Likewise, more patients
treated with ranibizumab from the beginning of the study
completed with a Snellen BCVA equivalent of 20/40 or better,
and fewer patients originally randomized to ranibizumab
completed month 36 with a Snellen BCVA of 20/200 or worse
(Fig 1 and Table 2).
At baseline, the mean time from ﬁrst known DME diagnosis to
study enrollment was 2.3 to 2.4 years in patients randomized to
sham (comparable to the baseline duration of DME in the groups
originally randomized to ranibizumab).7 Patients in the sham/
0.5 mg group thus had DME for approximately 4.5 years before
initiation of ranibizumab treatment. Because the sham crossover
group had received only 1 year of ranibizumab treatment,
a comparison was made to assess vision gains achieved after the
initial 12 months of treatment (Table 3). In pooled data from the
2 studies, the mean number of letters gained after 12 months of
monthly ranibizumab was 2.8 letters in the sham/0.5 mg group
compared with 10.6 and 11.1 letters in the ranibizumab 0.3 mg
and 0.5 mg groups, respectively. However, the conclusions that
can be drawn from this observation are limited because the
groups were no longer fully comparable.
In evaluating the response of the sham group to delayed rani-
bizumab therapy, it is notable that the average BCVA improve-
ments in the sham group showed relatively little gain after crossover
to 0.5 mg ranibizumab after month 24 (2.5 letters at month 24 and
4.5 letters at month 36 in the pooled RIDE/RISE population; Fig 3).
Because the primary analysis was ITT, the mean BCVA values may
have been affected by the last observation carried forward method
of imputing missing data where values from patients who had
discontinued from the sham group and did not receive treatment
were carried forward. To better understand the potential
improvements associated with ranibizumab use after 2 years of
sham treatment (plus laser, when indicated, in 70%e74% of
sham patients through month 247), an analysis was performed in
the subgroup of patients receiving 1 study drug injection after
month 24. Sham patients who received at least 1 study drug
injection after month 24 (n¼190) gained on average 7.5 (RIDE)2015
Figure 1. The visual acuity (VA) outcomes at 36 months: percentage of patients who gained 15 or more Early Treatment Diabetic Retinopathy Study
(ETDRS) letters from baseline VA at 36 months (top left), percentage of patients who lost 15 ETDRS letters from baseline VA at 36 months (top right),
percentage of patients with vision of the Snellen equivalent of 20/40 at 36 months (bottom left), and percentage of patients with vision of the Snellen
equivalent of 20/200 at 36 months (bottom right). Vertical bars are 95% conﬁdence intervals for the percentage. Differences shown are unadjusted for
stratiﬁcation variables. The last observation carried forward method was used to impute missing data.
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http://aaojournal.org). However, this is compared with a 12.1- to
15.6-letters average gain at month 36 in the similar subset of
patients originally randomized to ranibizumab who also received
at least 1 dose of study drug after month 24 (Fig 3).Anatomic Outcomes
The mean OCT thickness in the sham group at baseline was
447.4 mm in RIDE and 467.3 mm in RISE, matching that of the
originally randomized ranibizumab groups (all >450 mm). All
groups at baseline also were well matched with respect to mean
duration of DME (1.6e2.4 years) and prior therapy for DME
(68.8%e82% in each of the sham, 0.3 mg, and 0.5 mg groups).
After 12 months of monthly ranibizumab therapy, the sham/0.5 mg
group experienced a reduction (SD) of 98.4 mm (142.8)
compared with reductions of 237.9 mm (186.1) and 249.3 mm
(194.8) in the 0.3 and 0.5 mg groups, respectively (Table 3).
The average OCT CFT at month 24, after sham treatment but
before any ranibizumab exposure, was 292.5 mm in the sham
group compared with 463.8 and 478.6 mm at baseline in groups
originally randomized to ranibizumab. This may reﬂect the effect
of laser or thinning associated with ongoing retinal cell loss in the
diabetic retina. In patients originally randomized to ranibizumab,
the signiﬁcant reductions in CFT from baseline observed at month
24 also were maintained through month 36 (Fig 2). By using the
ITT analysis that carried forward the last observation from sham
patients who discontinued the study before month 24, OCT
reductions after crossover from sham injection to 0.5 mg
ranibizumab did not seem to be as great at month 36 as in
patients originally randomized to ranibizumab (Fig 2). When
considering only the subgroup of patients who received 12016study drug injection after month 24, observed OCT reductions
after sham crossover to ranibizumab were greater than those
seen using the ITT analysis, as shown by the steeper decline in
the mean OCT CFT curve (Fig 3). Of note, the OCT thicknesses
at month 36 were more similar among the groups: the sham/
0.5 mg group at month 36 had an average OCT thickness of
194.1 mm, compared with 223.4 mm in the 0.3 mg group and
201.9 mm in the 0.5 mg group.
Consistent with the 24-month outcomes, patients randomized to
ranibizumab were more likely to experience improvements in DR
severity as measured by the ETDRS retinopathy severity scale and
less likely to develop proliferative DR (Table 2). The sham
crossover group also demonstrated improvements in DR severity
after crossover to ranibizumab therapy (Table 2).Use of Macular and Panretinal Laser Treatment
Compared with patients who had been randomized to receive rani-
bizumab, a much greater proportion of sham patients had received
macular (19.7%e36% vs. 70% and 74%) or panretinal laser (0%e
1.6% vs. 11% and 12.3%) at month 24.7 These differences were
maintained through 36 months, largely as a result of the
difference in laser use during the 24-month sham-controlled
portion of the studies. Through 36 months, the proportion of
patients in the sham/0.5 mg group who received macular laser at
least once over 36 months was 72.3% in RIDE and 74.0% in RISE,
compared with 21.3% to 40.8% of patients originally randomized to
ranibizumab (Table 2). The proportion of patients in the sham/0.5
mg group who underwent panretinal laser was 13.8% in RIDE
and 12.6% in RISE over 36 months compared with 0.0% to 3.2%
in patients originally randomized to ranibizumab. The proportions
of patients receiving macular laser between months 24 and 36 was
Table 2. Key Efﬁcacy Outcomes at Month 36 in the Intent-to-Treat Population
RIDE RISE
Sham/0.5 mg
(N[130)
Ranibizumab
Sham/0.5 mg
(N[127)
Ranibizumab
0.3 mg
(N[125)
0.5 mg
(N[127)
0.3 mg
(N[125)
0.5 mg
(N[125)
VA Outcomes
Gaining 15 ETDRS
letters, n (%)
25 (19.2%) 46 (36.8%) 51 (40.2%) 28 (22.0%) 64 (51.2%) 52 (41.6%)
95% CI for percentage 12.5e26.0 28.3e45.3 31.6e48.7 14.8e29.3 42.4e60.0 33.0e50.2
ETDRS letters change
from baseline, (SD)
4.7 (13.3) 10.6 (12.9) 11.4 (16.3) 4.3 (14.9) 14.2 (12.8) 11.0 (12.9)
95% CI for mean 2.4e7.0 8.3e12.8 8.6e14.3 1.7e7.0 12.0e16.5 8.8e13.3
Gaining 10 ETDRS
letters, n (%)
43 (33.1%) 71 (56.8%) 80 (63.0%) 49 (38.6%) 87 (69.6%) 72 (57.6%)
95% CI for percentage 25.0e41.2 48.1e65.5 54.6e71.4 30.1e47.0 61.5e77.7 48.9e66.3
Loss of <15 ETDRS
letters, n (%)
120 (92.3%) 121 (96.8%) 122 (96.1%) 116 (91.3%) 124 (99.2%) 122 (97.6%)
95% CI for percentage 87.7e96.9 93.7e99.9 92.7e99.4 86.4e96.2 97.6e100 94.9e100
Snellen 20/40, n (%) 55 (42.3%) 69 (55.2%) 75 (59.1%) 54 (42.5%) 79 (63.2%) 74 (59.2%)
95% CI for percentage 33.8e50.8 46.5e63.9 50.5e67.6 33.9e51.1 54.7e71.7 50.6e67.8
Snellen 20/200, n (%) 9 (6.9%) 4 (3.2%) 5 (3.9%) 14 (11%) 5 (4.0%) 5 (4.0%)
95% CI for percentage 2.6e11.3 0.1e6.3 0.6e7.3 5.6e16.5 0.6e7.4 0.6e7.4
Anatomic Outcomes
Mean change in CFT
from baseline (SD), mm
213.2 (193.5) 261.8 (180.8) 266.7 (207.8) 200.1 (215.6) 261.2 (196.5) 269.1 (178.9)
95% CI for percentage 246.8 to 179.6 293.8 to 229.8 303.2 to 230.2 238.0 to 162.3 296.0 to 226.4 300.8 to 237.4
3-step progression on
ETDRS scale, n (%)*
4 (3.2%) 1 (0.9%) 1 (0.8%) 5 (4.3%) 2 (1.7%) 2 (1.7%)
95% CI for percentage 0.1e6.3 0.0e2.5 0.0e2.5 0.6e8.1 0.0e4.1 0.0e4.1
2 step progression on
ETDRS scale, n (%)*
11 (8.9%) 1 (0.9%) 2 (1.7%) 11 (9.6%) 5 (4.3%) 5 (4.3%)
95% CI for percentage 3.9e13.9 0.0e2.5 0.0e4.0 4.2e14.9 0.6e7.9 0.6e8.1
3-step improvement on
ETDRS scale, n (%)*
5 (4.0%) 17 (14.5%) 18 (15.1%) 3 (2.6%) 18 (15.4%) 13 (11.3%)
95% CI for percentage 0.6e7.5 8.1e20.9 8.7e21.6 0.0e5.5 8.8e21.9 5.5e17.1
2-step improvement on
ETDRS scale, n (%)*
29 (23.4%) 46 (39.3%) 45 (37.8%) 28 (24.3%) 45 (38.5%) 47 (40.9%)
95% CI for percentage 15.9e30.8 30.5e48.2 29.1e46.5 16.5e32.2 29.6e47.3 31.9e49.9
Progression to PDR by
ophthalmoscopy, n (%)
18 (13.8%) 6 (4.8%) 7 (5.5%) 22 (17.3%) 3 (2.4%) 9 (7.2%)
95% CI for percentage 7.9e19.8 1.1e8.5 1.5e9.5 10.7e23.9 0.0e5.1 2.7e11.7
Laser Treatment
Patients who received
macular laser, n (%)
94 (72.3%) 46 (36.8%) 27 (21.3%) 94 (74.0%) 51 (40.8%) 47 (37.6%)
95% CI for percentage 64.6e80.0 28.3e45.3 14.1e28.4 66.4e81.6 32.2e49.4 29.1e46.1%
Patients who received
PRP laser, n (%)
18 (13.8%) 4 (3.2%) 3 (2.4%) 16 (12.6%) 0 3 (2.4%)
95% CI for percentage 7.9e19.8 0.1e6.3 0.0e5.0 6.8e18.4 0.0e0.0 0.0e5.1
CFT ¼ central foveal thickness; CI ¼ conﬁdence interval; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; PDR ¼ proliferative diabetic reti-
nopathy; PRP ¼ panretinal photocoagulation; VA ¼ visual acuity.
The last observation carried forward method was used to impute missing data. Stratiﬁcation variables in stratiﬁed analyses: baseline VA (55 or>55 letters),
baseline hemoglobin A1c (8%, >8%), and prior treatment for DME (yes, no).
*N ¼ 124, 117, and 119 (RIDE) and 115, 117, and 115 (RISE) for sham/0.5 mg, 0.3 mg, and 0.5 mg groups, respectively.
Brown et al  Three Years of Ranibizumab for DME5.5% to 9.4% across all treatment groups among patients who
received at least 1 dose of study drug after month 24. Likewise,
the proportions of patients who had received at least 1 dose of
study drug after month 24 and underwent panretinal laser between
months 25 and 36 was 0% to 2.2% among all groups.
Safety Outcomes
Safety data collected through month 36 were evaluated to
assess whether the longer-term safety proﬁle of ranibizumabwas consistent with that initially observed and to further assess
the relative long-term safety of ongoing monthly 0.3 mg and 0.5
mg ranibizumab doses. Because the majority of patients in the
sham group crossed over to monthly 0.5 mg ranibizumab
dosing after month 24 and received 12 months of exposure
compared with 36 months of exposure in the originally
randomized groups, comparisons between the groups need to be
interpreted with caution because the populations are not directly
comparable with respect to the duration of ranibizumab
exposure.2017
Figure 2. Mean change in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) from baseline over time. Vertical bars are 95%
conﬁdence intervals. Missing data were imputed by last observation carried forward.
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Key study eye ocular safety data are summarized in Table 4
(available at http://aaojournal.org). The ocular safety proﬁle was
consistent with the sham-controlled safety observations from the
24-month analysis. In particular, rates of procedure-related serious
adverse events (SAEs), such as endophthalmitis and traumatic
cataract, remained low. The total number of patients in the rani-
bizumab treatment groups experiencing endophthalmitis or trau-
matic cataract in the study eye over the 36-month treatment period
across both studies was 6 (1.2%) and 4 (0.8%), respectively. The
per-injection rate of endophthalmitis was approximately 0.06%,
whereas the per-injection rate of traumatic cataract was 0.03%
(Table 5, available at http://aaojournal.org). Similar proportions of
the patients randomized to ranibizumab reported an adverse event
(AE) of increased intraocular pressure at months 24 and 36
(Table 4, available at http://aaojournal.org). The mean pre-dose
intraocular pressure in the study eye at month 36 in the sham
and crossover to 0.5 mg, 0.3 mg, and 0.5 mg groups was
15.4 mmHg, 15.5 mmHg, and 14.9 mmHg, respectively.
Systemic Safety
The long-term systemic safety of ranibizumab in DME was eval-
uated using 2 methods. As in previous studies of intravitreal
ranibizumab across several retinal vascular diseases, we ﬁrst
assessed rates of arterial thromboembolic events (ATEs) using the
Antiplatelet Trialists’ Collaboration (APTC) classiﬁcation,17 which
is based on a speciﬁc and well-deﬁned spectrum of ATE AEs:
vascular deaths (including deaths of unknown cause), nonfatal
myocardial infarction, and nonfatal stroke (Table 6). Overall
APTC-classiﬁed AEs occurred in 7.2%, 10.8%, and 10.4% of
patients in the sham/0.5 mg, 0.3 mg, and 0.5 mg groups, respec-
tively. Among APTC-classiﬁed events occurring over 36 months,
deaths of vascular and unknown causes occurred in 2%, 3.6%, and
3.6% of patients in the sham/0.5 mg, 0.3 mg, and 0.5 mg2018ranibizumab groups, respectively. The overall incidence of deaths
through 36 months, including deaths from nonvascular causes, was
4.4% (11 patients) in the monthly 0.3 mg group, 6.4% (16 patients)
in the 0.5 mg group, and 2.8% (7 patients) in the sham/0.5 mg
group (Table 7, available at http://aaojournal.org). Causes of death,
listed in Table 7, were mostly consistent with those typical of
patients with advanced complications of diabetes.18 Rates of
stroke over 3 years were higher in the 0.5 mg group (12 [4.8%])
compared with the 0.3 mg group (5 [2.0%]) or sham/0.5 mg
group (6 [2.4%]) (Table 6). The incidence of myocardial
infarction through month 36 was 18 (7.2%) in the 0.3 mg group
and 9 (3.6%) in the 0.5 mg group (Table 6).
Although the APTC classiﬁcation system provides useful insight
into the systemic safety of intraocular anti-VEGF therapy, a more
thorough understanding of systemic anti-VEGF safety has devel-
oped over the last several years, primarily because of the use of
intravenous agents in oncology. As clinical experience with
systemic anti-VEGF agents has grown, additional types and cate-
gories of systemic AEs potentially associated with the use of
systemic anti-VEGF treatment have been identiﬁed. These are
considered “class” effects related to systemic VEGF inhibition.19
Categories of these anti-VEGF class-related AEs include hyper-
tension, proteinuria, arterial and venous thromboembolic events,
bleeding/hemorrhage (central nervous system and cerebrovascular,
nonecentral nervous system), congestive heart failure, ﬁstulae,
gastrointestinal perforation, and wound-healing complications.
Categorizing SAEs using this second broader approach demon-
strated that the overall incidence of SAEs potentially related to
systemic VEGF inhibition was higher in patients who received
0.5 mg ranibizumab compared with 0.3 mg ranibizumab or sham/
0.5 mg: 49 of 249 (19.7%) versus 42 of 250 (16.8%) and 33 of 251
(13.1%) (Table 8, available at http://aaojournal.org). The incidence
of several categories (central nervous system and cerebrovascular
hemorrhage, congestive heart failure, hypertension, gastrointestinal
perforation, proteinuria, and wound-healing complications) ap-
peared to increase in a dose-dependent fashion in patients with
Figure 3. Mean change in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) from baseline over time in the RIDE and RISE pooled
population and the subgroup of patients receiving 1 study drug injection after month 24. Vertical bars are 95% conﬁdence intervals. Missing data were
imputed by last observation carried forward. ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
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latter 3 categories, only 1 SAE in the 0.5 mg group was observed.Discussion
The 36-month results from the RIDE and RISE studies
demonstrate that the rapid and sustained efﬁcacy of ranibi-
zumab in patients with DME initially observed at 2 years is
maintained over an additional third year of continued
monthly treatment. A gain of 15 letters from baseline was
experienced by 36.8% to 51.2% of ranibizumab-treated
patients, and the incidence of further vision loss was signif-
icantly reduced in ranibizumab-treated eyes. Poor BCVA
outcomes (such as BCVA worse than by Snellen <20/200)
occurred in fewer patients initially treated with ranibizumab,
conﬁrming the long-term abilities of ranibizumab to improvevision and prevent signiﬁcant vision loss in patients with
DME. Reductions in retinal edema on OCT and improve-
ments in DR severity also were maintained through 36
months.
The 36-month results provide important clinical insights
into treatment outcomes after a 24-month delay in initiation
of ranibizumab therapy in the sham crossover group. The
relatively limited improvements in vision in this group,
compared with the groups initially treated with ranibizumab,
suggest that chronic retinal edema (for an average of 4.5 years
before ranibizumab therapy) may result in a certain amount of
potential vision gain being irreversibly lost. Retinal atrophy
due to chronic edema may provide an explanation for this
ﬁnding. Although OCT measurements in the sham crossover
group after ranibizumab treatment showed a reduction in
absolute CFT to a mean value of 190 mm (approximately
20 mm less than that observed after treatment in the2019
Table 3. Changes in the Study Eye at 12 Months After the First Dose of Ranibizumab for Key Efﬁcacy Outcomes (RIDE and RISE Pooled)
Sham and Crossover to 0.5 mg (N[191)
Ranibizumab
0.3 mg (N¼250) 0.5 mg (N¼252)
Total No. of ranibizumab injections by ﬁrst 12-mo ranibizumab
treatment, mean (SD)*
10.0 (2.0) 10.6 (2.6) 10.9 (2.2)
BCVA (ETDRS letters)
Before ranibizumab treatment,y mean (SD) 62.0 (15.3) 56.1 (12.2) 56.9 (11.6)
12-mo after ranibizumab treatment, mean (SD) 64.8 (14.8) 67.8 (15.0) 68.9 (14.1)
Change from before treatment, mean (SD) 2.8 (9.8) 10.6 (10.6) 11.1 (10.1)
Gain of 15 letters from before treatment, n (%) 14 (7.3) 81 (32.4) 80 (31.7)
CFT (mm), mean (SD)
Before ranibizumab treatmenty 292.5 (167.2) 478.6 (162.3) 463.8 (160.4)
12-mo after ranibizumab treatment 194.1 (118.2) 223.4 (136.2) 201.9 (107.3)
Change from before treatment 98.4 (142.8) 237.9 (186.1) 249.3 (194.8)
BCVA ¼ best-corrected visual acuity; CFT ¼ central foveal thickness; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SD ¼ standard deviation.
*Actual treatment duration for sham crossover groups is 11 months.
yMonth 24 for the sham/0.5 mg group, baseline for the 0.3 mg, and 0.5 mg groups.
Ophthalmology Volume 120, Number 10, October 2013groups originally randomized to ranibizumab), the average
improvement in BCVA was considerably smaller than that
achieved in the originally treated cohorts. This outcome may
represent the effect of several potential factors: neural cell
loss over time in the diabetic retina, compounded by the
effects of chronic edema (including neuronal retinal damage,
retinal pigment epithelium pigmentation, and/or subretinal
ﬁbrosis), additional structural changes induced by repeated
macular laser, and/or the natural history of DR.
In the phase III trials of ranibizumab in the treatment of age-
related macular degeneration and retinal vein occlusion, there
appeared to be a dose response curve favoring 0.5 mg over 0.3
mg ranibizumab for optimum efﬁcacy. However, in the pooled
data from the RIDE and RISE trials, efﬁcacy was equivalent
between the 0.3-mg and 0.5-mgdoses. The comparative proﬁle
of the 2 doses of ranibizumab in DME was assessed usingTable 6. Antiplatelet Trialists’ Collaboration (APTC) Ev
Category/Event
Sham Months 0L24
(N[250)
Sham/0.5 mg* Months 0L
(N[251y)
Total APTC-classiﬁed
events
13 (5.2%) 18 (7.2%)
Deaths 3 (1.2%) 7 (2.8%)
Vascular 3 (1.2%) 5 (2.0%)
Nonvascular 0 2 (0.8%)
Unknown cause 0 0
Myocardial infarction 9 (3.6%) 13 (5.2%)
Fatal 2 (0.8%) 4 (1.6%)
Nonfatal 7 (2.8%) 9 (3.6%)
Stroke (CVA) 4 (1.6%) 6 (2.4%)
Fatal 1 (0.4%) 2 (0.8%)
Nonfatal 3 (1.2%) 4 (1.6%)
CVA ¼ cerebrovascular accident.
APTC events include vascular deaths, deaths of unknown cause, nonfatal myo
*Patients initially randomized to sham including those who crossed over to ranib
36, so it is not valid to compare the sham groups with the ranibizumab treatm
yOne sham patient received 0.5 mg ranibizumab starting at month 23. This patie
per the prespeciﬁed deﬁnition of treatment groups for safety analyses. For the 36
thus was classiﬁed in the sham/0.5 mg crossover group.
2020a structured, systematic approach based on the Beneﬁt Risk
Action Team framework (Fig 4AeC, available at http://
aaojournal.org).20,21 These ﬁgures help demonstrate that,
although concentrations of ranibizumab in the systemic
circulation are lower than vitreous concentrations, the use of
0.3 mg may reduce risks potentially related to systemic VEGF
suppression while still maintaining optimal efﬁcacy. This may
beparticularly appropriate in themanagement ofDMEbecause
not only do 40% to 50% of patients with DME have bilateral
disease requiring contemporaneous treatment,22 but also
diabetic patients have an underlying increased risk of
mortality and cardiovascular disease, including stroke and
silent myocardial ischemia.23 In light of these considerations,
Genentech recommended the 0.3-mg dose; the US Food and
Drug Administration ultimately approved use of 0.3 mg
ranibizumab for DME on August 10, 2012.ents through Month 36 (Safety-Evaluable Population)
36 Ranibizumab
0.3 mg Months 036 (N¼250) 0.5 mg Months 036 (N¼249)
27 (10.8%) 26 (10.4%)
11 (4.4%) 16 (6.4%)
8 (3.2%) 8 (3.2%)
2 (0.8%) 7 (2.8%)
1 (0.4%) 1 (0.4%)
18 (7.2%) 9 (3.6%)
3 (1.2%) 1 (0.4%)
15 (6.0%) 8 (3.2%)
5 (2.0%) 12 (4.8%)
1 (0.4%) 3 (1.2%)
4 (1.6%) 9 (3.6%)
cardial infarctions, and nonfatal strokes.
izumab 0.5 mg during year 3. There is no pure sham control group at month
ent arms.
nt was classiﬁed in the ranibizumab 0.5 mg group for the 24-month analyses
-month analyses, it was determined that this patient crossed over early and
Brown et al  Three Years of Ranibizumab for DMEStudy Limitations
As with all clinical trials, certain limitations exist in extrap-
olating the RIDE and RISE study observations to routine
clinical practice. One potential limitation is that some
patients discontinued their participation, with 67.7% to
80.0% of patients completing month 36 across the various
treatment groups. However, interpretation of the study
results did not change when performing sensitivity analyses
using a variety of methods for missing data imputation (data
not shown). A more important potential limitation is that
ranibizumab was administered on a continuous monthly
dosing schedule, which may optimize efﬁcacy but not be
practical for many patients with DME. However, additional
large phase III and phase III-scope studies using 0.5 mg with
less than monthly dosing have provided important additional
data on the efﬁcacy and safety of ranibizumab in DME.5,6,8,24
For example, in the DRCRnet study of ranibizumab, macular
laser, or triamcinolone for DME, signiﬁcant visual acuity
beneﬁts were observed with a median of 8 to 9 ranibizumab
injections in the ﬁrst year, 2 to 3 injections in the second year,
and 1 to 2 injections in the third year.5,9,14 In the RESTORE
phase III study of DME, which compared 0.5 mg ranibizu-
mab (with individualized pro re nata dosing) with or without
macular laser with laser alone, signiﬁcant improvements in
BCVA and OCT outcomes were observed with ranibizumab
with an average of 6.8 to 7.0 injections over 12 months.6
Mean BCVA gain was maintained or improved through 36
months.25 These studies also provide insights into the
systemic safety of ranibizumab in separate DME
populations enrolled and studied contemporaneously with
RIDE and RISE. No systemic safety imbalances emerged
with 0.5 mg ranibizumab dosed on a less than monthly
basis compared with control in the DRCRnet Protocol I or
RESTORE studies. In DRCRnet Protocol I, patients in the
sham group experienced higher rates of APTC-classiﬁed
systemic events than patients receiving ranibizumab.14 In
RESTORE, no meaningful differences in the number of
ATEs or other systemic events potentially related to VEGF
inhibition were observed between the ranibizumab and
laser control groups, although patients with a history of
stroke or transient ischemic attack were excluded from this
study (Abstract PO532. Annual Meeting of the American
Academy of Ophthalmology, November 10e13, 2012,
Chicago, IL).6 Forthcoming data from the open-label
extension phase of RIDE and RISE, in which ranibizumab
is administered less frequently, will also contribute infor-
mation on this question.
Another limitation is that it is unknown whether the
results with ranibizumab for the management of DME as
demonstrated in RIDE and RISE are applicable to other anti-
VEGF agents. The various commonly used intravitreal anti-
VEGFs have different molecular characteristics, leading to
differences in potency, systemic clearance, and systemic
VEGF inhibition.25 To help address these questions,
a comparative study of 3 anti-VEGF agents for DME is
now being recruited by the Diabetic Retinopathy Clinical
Research Network (NCT01627249).26
In conclusion, the 36-month results of RIDE and RISE
conﬁrm the long-term efﬁcacy and safety of ranibizumab inDME. These data further highlight the importance of
expanding DR screening programs and greater awareness of
and adherence to already-recommended national screening
guidelines. Recent reports suggest that 93% of patients with
DR and 63% of patients with vision-threatening DR were
unaware they had DR; 83% with vision-threatening DR had
no scheduled follow-up eye examination (Abstract 1287/A37.
Association for Research in Vision and Ophthalmology
Annual Meeting, May 1e5, 2011, Fort Lauderdale, FL).
Prompt treatment with anti-VEGF therapy at the time of
initial diagnosis may avoid the considerable visual morbidity
associated with chronic DME. Ophthalmologists now have
considerable evidence from multiple clinical studies demon-
strating that intraocular anti-VEGF therapy with ranibizumab
offers a new and substantially better approach to the treatment
of DME, one of the leading causes of vision loss in working-
aged adults, and thus has set a new standard of care for DME.References
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